Cara Haymaker

Sep 6, 2024 | digitalcommons.library.tmc.edu | Jose A. Karam |Pavlos Msaouel |Cara Haymaker |Surena F. Matin

Sitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in combination with nivolumab in patients with locally advanced clear cell renal cell carcinoma (ccRCC) prior to curative nephrectomy (NCT03680521).

Mar 21, 2024 | biorxiv.org | Qingnan Liang |Luisa Solis Soto |Cara Haymaker |Ken Chen

AbstractCellular anatomy and signaling vary across niches, which can induce gradated gene expressions in subpopulations of cells. Such spatial transcriptomic gradient (STG) makes a significant source of intra-tumor heterogeneity and can influence tumor invasion, progression, and response to treatment.

May 10, 2023 | nature.com | Jose A. Karam |Pavlos Msaouel |Cara Haymaker |Surena F. Matin |Matthew Campbell |Amado J. Zurita | +4 more

AbstractSitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in combination with nivolumab in patients with locally advanced clear cell renal cell carcinoma (ccRCC) prior to curative nephrectomy (NCT03680521).